L-arginine plus drospirenone-ethinyl estradiol in the treatment of patients with PCOS: A prospective, placebo controlled, randomised, pilot study.

Trial Profile

L-arginine plus drospirenone-ethinyl estradiol in the treatment of patients with PCOS: A prospective, placebo controlled, randomised, pilot study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Mar 2011

At a glance

  • Drugs Arginine (Primary) ; Drospirenone/ethinylestradiol (Primary)
  • Indications Cardiovascular disorders; Polycystic ovary syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top